PMID- 29804123
OWN - NLM
STAT- MEDLINE
DCOM- 20190116
LR  - 20221207
IS  - 1423-0267 (Electronic)
IS  - 0030-3755 (Linking)
VI  - 240
IP  - 4
DP  - 2018
TI  - Aflibercept Treatment in Polypoidal Choroidal Vasculopathy: Results of a 
      Prospective Study in a Caucasian Population.
PG  - 208-212
LID - 10.1159/000488808 [doi]
AB  - INTRODUCTION: Polypoidal choroidal vasculopathy (PCV) is a choroidal pathology 
      characterized by frequent occurrences of subretinal hemorrhages and resistance to 
      monotherapies such as ranibizumab or bevacizumab intravitreal injections (IVT). 
      The purpose of this study is to evaluate both the anatomical and functional 
      efficacy of aflibercept IVT as a monotherapy in PCV in a Caucasian population. 
      METHODS: We conducted a prospective multicenter study in either treatment-naive 
      patients with PCV or PVC patients who had not been treated with anti-VEGF within 
      the previous 3 months or with photodynamic therapy (PDT) within the previous 6 
      months. All patients had been treated with 3 initial monthly loading doses of 
      aflibercept followed by a Q8 regimen for 28 weeks in total. All patients 
      underwent a complete ophthalmic examination including the measurement of 
      best-corrected visual acuity (BCVA) before each IVT and after 28 weeks as well as 
      an optical coherent tomography (OCT) of the macula. At baseline and 28 weeks, the 
      polypoidal dilations were analyzed with indocyanine green angiography. RESULTS: 
      Thirty-four eyes of 34 patients were included in this study. All patients were 
      followed for 28 weeks and received 5 aflibercept IVT. The mean baseline BCVA was 
      55 letters. After 28 weeks, significant +13 letters in BCVA and a regression of 
      exudative signs on OCT in all patients were observed. In 62% of the cases, polyp 
      disappearance was observed on indocyanine green angiography. DISCUSSION: In this 
      study on a Caucasian population, we showed that aflibercept as a monotherapy 
      provided both a significant visual gain and the regression of polypoidal 
      dilations. Aflibercept use in monotherapy may contribute to reduce the 
      hemorrhagic risk and atrophy linked to PDT.
CI  - (c) 2018 S. Karger AG, Basel.
FAU - Wolff, Benjamin
AU  - Wolff B
AD  - Ophthalmologic Center Maison Rouge, Strasbourg, Francebwolff@hotmail.fr.
FAU - Vasseur, Vivien
AU  - Vasseur V
AD  - Adolphe de Rothschild Foundation, CIC Department, Paris, France.
FAU - Cahuzac, Armelle
AU  - Cahuzac A
AD  - Adolphe de Rothschild Foundation, CIC Department, Paris, France.
FAU - Coscas, Florence
AU  - Coscas F
AD  - Odeon Ophthalmologic Center, Paris, France.
FAU - Castelnovo, Laurent
AU  - Castelnovo L
AD  - Ophthalmologic Center Maison Rouge, Strasbourg, France.
FAU - Favard, Catherine
AU  - Favard C
AD  - Odeon Ophthalmologic Center, Paris, France.
FAU - Michel, Guillaume
AU  - Michel G
AD  - Ophthalmologic Center Maison Rouge, Strasbourg, France.
FAU - Francais, Catherine
AU  - Francais C
AD  - Odeon Ophthalmologic Center, Paris, France.
FAU - Salomon, Laurence
AU  - Salomon L
AD  - Adolphe de Rothschild Foundation, CIC Department, Paris, France.
FAU - Mauget-Faysse, Martine
AU  - Mauget-Faysse M
AD  - Adolphe de Rothschild Foundation, CIC Department, Paris, France.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20180525
PL  - Switzerland
TA  - Ophthalmologica
JT  - Ophthalmologica. Journal international d'ophtalmologie. International journal of 
      ophthalmology. Zeitschrift fur Augenheilkunde
JID - 0054655
RN  - 0 (Recombinant Fusion Proteins)
RN  - 15C2VL427D (aflibercept)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Choroid/*blood supply
MH  - Choroid Diseases/diagnosis/*drug therapy
MH  - Female
MH  - Fluorescein Angiography
MH  - Follow-Up Studies
MH  - Fundus Oculi
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Polyps/diagnosis/*drug therapy
MH  - Prospective Studies
MH  - Receptors, Vascular Endothelial Growth Factor/*administration & 
      dosage/antagonists & inhibitors
MH  - Recombinant Fusion Proteins/*administration & dosage
MH  - Time Factors
MH  - Tomography, Optical Coherence
MH  - *Visual Acuity
MH  - White People
OTO - NOTNLM
OT  - Aflibercept
OT  - Caucasian population
OT  - Indocyanine green angiography
OT  - Optical coherent tomography
OT  - Polypoidal choroidal vasculopathy
OT  - Prospective study
EDAT- 2018/05/29 06:00
MHDA- 2019/01/17 06:00
CRDT- 2018/05/28 06:00
PHST- 2017/12/22 00:00 [received]
PHST- 2018/03/26 00:00 [accepted]
PHST- 2018/05/29 06:00 [pubmed]
PHST- 2019/01/17 06:00 [medline]
PHST- 2018/05/28 06:00 [entrez]
AID - 000488808 [pii]
AID - 10.1159/000488808 [doi]
PST - ppublish
SO  - Ophthalmologica. 2018;240(4):208-212. doi: 10.1159/000488808. Epub 2018 May 25.